Clinical Trial Update: The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenalidomide monotherapy in red blood cell transfusion dependent MDS with del(5q) shows efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: King's College Hospital NHS Trust | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED